Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ceftazidime Anhydrous
2. Ceftazidime Pentahydrate
3. Fortaz
4. Fortum
5. Gr 20263
6. Gr-20263
7. Gr20263
8. Ly 139381
9. Ly-139381
10. Ly139381
11. Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, Inner Salt, Pentahydrate, (6r-(6alpha,7beta(z)))-
12. Tazidime
1. 72558-82-8
2. Tazidime
3. Fortaz
4. Ceftazidime Anhydrous
5. Pentacef
6. Tazicef
7. Ceptaz
8. Ceftazidima
9. Ceftazidimum
10. Ceftazidime Pentahydrate
11. Gr 20263
12. Chebi:3508
13. (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
14. Fortaz (tn)
15. (6r,7r)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
16. 7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
17. Gr-20263
18. Ly-139381
19. 78439-06-2
20. Caz
21. J01dd07
22. Nsc-759260
23. Ceftazidime (tn)
24. Ceptaz (tn)
25. Schembl36849
26. Bidd:gt0734
27. Chembl44354
28. Dtxsid5022770
29. Hms2090m13
30. (6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
31. Hy-b0593
32. Bdbm50420259
33. Akos015951273
34. Ccg-269983
35. Db00438
36. Ncgc00179584-05
37. Ceftazidime (arginine Formulation)
38. Ab00513848
39. C06889
40. D07654
41. Ab00513848-02
42. Cefprozil, Antibiotic For Culture Media Use Only
43. A839420
44. Q-200811
45. (6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (contains Ca. 10% Na2co3)
46. (6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate(containsca.10%na2co3)
47. (6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
48. 1-{[(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium
49. 7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
Molecular Weight | 546.6 g/mol |
---|---|
Molecular Formula | C22H22N6O7S2 |
XLogP3 | 0.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 8 |
Exact Mass | 546.09913941 g/mol |
Monoisotopic Mass | 546.09913941 g/mol |
Topological Polar Surface Area | 245 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 1020 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 8 | |
---|---|
Drug Name | Ceftazidime |
PubMed Health | Ceftazidime (Injection) |
Drug Classes | Antibiotic |
Drug Label | Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It isthe pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy) imino] acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabic... |
Active Ingredient | Ceftazidime |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial; 6gm/vial |
Market Status | Prescription |
Company | Wockhardt; Acs Dobfar |
2 of 8 | |
---|---|
Drug Name | Fortaz |
PubMed Health | Ceftazidime (Injection) |
Drug Classes | Antibiotic |
Drug Label | Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicycl... |
Active Ingredient | Ceftazidime |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial; 6gm/vial |
Market Status | Prescription |
Company | Covis Injectables |
3 of 8 | |
---|---|
Drug Name | Fortaz in plastic container |
PubMed Health | Ceftazidime (Injection) |
Drug Classes | Antibiotic |
Drug Label | Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicycl... |
Active Ingredient | Ceftazidime sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 40mg base/ml; eq 20mg base/ml |
Market Status | Prescription |
Company | Covis Injectables |
4 of 8 | |
---|---|
Drug Name | Tazicef |
Active Ingredient | Ceftazidime |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial; 6gm/vial |
Market Status | Prescription |
Company | Hospira |
5 of 8 | |
---|---|
Drug Name | Ceftazidime |
PubMed Health | Ceftazidime (Injection) |
Drug Classes | Antibiotic |
Drug Label | Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It isthe pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy) imino] acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabic... |
Active Ingredient | Ceftazidime |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial; 6gm/vial |
Market Status | Prescription |
Company | Wockhardt; Acs Dobfar |
6 of 8 | |
---|---|
Drug Name | Fortaz |
PubMed Health | Ceftazidime (Injection) |
Drug Classes | Antibiotic |
Drug Label | Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicycl... |
Active Ingredient | Ceftazidime |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial; 6gm/vial |
Market Status | Prescription |
Company | Covis Injectables |
7 of 8 | |
---|---|
Drug Name | Fortaz in plastic container |
PubMed Health | Ceftazidime (Injection) |
Drug Classes | Antibiotic |
Drug Label | Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicycl... |
Active Ingredient | Ceftazidime sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 40mg base/ml; eq 20mg base/ml |
Market Status | Prescription |
Company | Covis Injectables |
8 of 8 | |
---|---|
Drug Name | Tazicef |
Active Ingredient | Ceftazidime |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/vial; 2gm/vial; 1gm/vial; 6gm/vial |
Market Status | Prescription |
Company | Hospira |
Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria. Ceftazidime is indicated in combination with [avibactam] to treat infections caused by susceptible Gram-negative organisms, including complicated intra-abdominal infections (cIAI), in conjunction with [metronidazole], and complicated urinary tract infections (cUTI), including pyelonephritis, in patients aged three months and older. This combination is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older. In all cases, to mitigate the risk of bacterial resistance and preserve clinical efficacy, ceftazidime should only be used for infections that are confirmed or strongly suspected to be caused by susceptible bacterial strains.
FDA Label
Ceftazidime is a semisynthetic, broad-spectrum, third-generation cephalosporin antibiotic that is bactericidal through inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin-binding protein 3 (PBP3). Among cephalosporins, ceftazidime is notable for its resistance to numerous -lactamases and its broad spectrum of activity against Gram-negative bacteria, including _Pseudomonas aeruginosa_. However, it is less active than first- and second-generation cephalosporins against _Staphylococcus aureus_ and other Gram-positive bacteria and also has low activity against anaerobes. Ceftazidime has confirmed activity against clinically relevant Gram-negative bacteria including _Citrobacter_ spp., _Enterobacter_ spp., _Klebsiella_ spp., _Proteus_ spp., _Serratia spp., _Escherichia coli_, _Haemophilus influenzae_, _Neisseria meningitidis_, _Pseudomonas aeruginosa_, and some Gram-positive bacteria including _Staphylococcus_ spp. and _Streptococcus_ spp. There are also _in vitro_ data for ceftazidime efficacy against a wide variety of other bacteria, such as _Acinetobacter baumannii_ and _Neisseria gonorrhoeae_, but no clear clinical studies to support the use of ceftazidime for infections caused by these bacteria. Although -lactam antibiotics like ceftazidime are generally well tolerated, there remains a risk of serious acute hypersensitivity reactions, which is higher in patients with a known allergy to ceftazidime or any other -lactam antibiotic. As with all antibiotics, ceftazidime may result in the overgrowth of non-susceptible organisms and potentially serious effects including _Clostridium difficile_-associated diarrhea (CDAD); CDAD should be considered in patients who develop diarrhea and, in confirmed cases, supportive care initiated immediately. Ceftazidime is primarily renally excreted such that high and prolonged serum concentrations can occur in patients with renal insufficiency, leading to seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia. Treatment may lead to the development or induction of resistance with a risk of treatment failure. Periodic susceptibility testing should be considered, and monotherapy failure may necessitate the addition of another antibiotic such as an aminoglycoside. Cephalosporin use may decrease prothrombin activity, which may be improved by exogenous vitamin K. Inadvertent intra-arterial administration of ceftazidime may result in distal necrosis.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DD - Third-generation cephalosporins
J01DD02 - Ceftazidime
Absorption
Ceftazidime administered intravenously in healthy males produced mean Cmax values of between 42 and 170 g/mL for doses between 500 mg and 2 g, and are reached immediately following the end of the infusion period. The Cmax for 1 g of ceftazidime administered intramuscularly is attained approximately one hour following injection and is between 37 and 43 mg/L. Following intramuscular administration of 500 mg and 1 g of ceftazidime, the serum concentration remained above 4 g/mL for six and eight hours, respectively. Ceftazidime Cmax and AUC show linear proportionality to the dose over the therapeutic range. In individuals with normal renal function, ceftazidime given intravenously every eight hours for 10 days as either 1 or 2 g doses showed no accumulation.
Route of Elimination
Approximately 80% to 90% of an intramuscular or intravenous dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. When administered intravenously, 50% of the dose appears in the urine within two hours, with another 32% of the dose appearing by eight hours post-administration.
Volume of Distribution
Ceftazidime has a volume of distribution of 15-20 L.
Clearance
The mean renal clearance of ceftazidime in healthy subjects ranges from 72 to 141 mL/min while the calculated plasma clearance is approximately 115 mL/min.
Ceftazidime is not appreciably metabolized.
Ceftazidime has an elimination half-life of 1.5-2.8 hours in healthy subjects. As ceftazidime is primarily renally excreted, its half-life is significantly prolonged in patients with renal impairment. In patients with creatinine clearance < 12 mL/min, the half-life is prolonged to between 14 and 30 hours.
The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan. Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal. Ceftazidime is a semisynthetic third-generation cephalosporin with broad activity against numerous Gram-negative and some Gram-positive bacteria. Like other -lactam antibiotics, ceftazidime exhibits its bactericidal effect primarily through direct inhibition of specific PBPs in susceptible bacteria. _In vitro_ experiments in Gram-negative bacteria such as _Escherichia coli_, _Pseudomonas aeruginosa_, _Acinetobacter baumannii_, and _Klebsiella pneumoniae_ suggest that ceftazidime primarily binds to PBP3, with weaker binding to PBP1a/1b and PBP2 as well; although binding to other PBPs, such as PBP4, is detectable, the concentrations required are much greater than those achieved clinically. Similarly, ceftazidime showed binding to _Staphylococcus aureus_ PBP 1, 2, and 3 with a much lower affinity for PBP4. Recent data for _Mycobacterium abcessus_ suggest that ceftazidime can inhibit PonA1, PonA2, and PbpA at intermediate concentrations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-02-29
Pay. Date : 2024-02-23
DMF Number : 23294
Submission : 2009-12-24
Status : Active
Type : II
Certificate Number : CEP 2005-028 - Rev 05
Issue Date : 2024-09-06
Type : Chemical
Substance Number : 1405
Status : Valid
Date of Issue : 2019-07-22
Valid Till : 2022-07-21
Written Confirmation Number : WC-0131
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39408
Submission : 2024-01-25
Status : Active
Type : II
Certificate Number : CEP 2009-234 - Rev 01
Issue Date : 2024-09-09
Type : Chemical
Substance Number : 2344
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7115
Submission : 1987-08-24
Status : Active
Type : II
Certificate Number : R1-CEP 2001-252 - Rev 04
Issue Date : 2015-06-15
Type : Chemical
Substance Number : 1405
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13009
Submission : 1998-05-25
Status : Active
Type : II
Certificate Number : R1-CEP 2010-272 - Rev 01
Issue Date : 2019-05-03
Type : Chemical
Substance Number : 2344
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16082
Submission : 2002-08-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24787
Submission : 2011-03-22
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-10
Pay. Date : 2013-09-06
DMF Number : 20481
Submission : 2006-12-28
Status : Active
Type : II
Certificate Number : R1-CEP 2010-125 - Rev 03
Issue Date : 2021-01-06
Type : Chemical
Substance Number : 2344
Status : Valid
Registration Number : 302MF10077
Registrant's Address : No. 849 Dongjia Town, Licheng District, Jinan, Shandong, China
Initial Date of Registration : 2020-07-06
Latest Date of Registration : --
NDC Package Code : 51810-006
Start Marketing Date : 2020-04-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16794
Submission : 2003-08-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25710
Submission : 2011-12-29
Status : Inactive
Type : II
Certificate Number : R1-CEP 2011-390 - Rev 00
Issue Date : 2018-11-21
Type : Chemical
Substance Number : 1405
Status : Withdrawn by Holder
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2020-06-02
Registration Number : 20200602-210-J-645
Manufacturer Name : Liaoning Medya Pharmaceutical Co., Ltd
Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do @Technology City, Fushun Economic Development Zone, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17628
Submission : 2004-08-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13683
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19998
Submission : 2006-11-17
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-16
Pay. Date : 2014-05-05
DMF Number : 20985
Submission : 2007-10-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13650
Submission : 2000-08-10
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-02-29
Pay. Date : 2024-02-23
DMF Number : 23294
Submission : 2009-12-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-12-10
Pay. Date : 2013-09-06
DMF Number : 20481
Submission : 2006-12-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13009
Submission : 1998-05-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7115
Submission : 1987-08-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16082
Submission : 2002-08-06
Status : Active
Type : II
Ceftazidime Pentahydrate, Sterile
Certificate Number : R1-CEP 2007-088 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2013-10-18
Type : Chemical
Substance Number : 1405
Ceftazidime Pentahydrate, Sterile
Certificate Number : R1-CEP 2004-129 - Rev 07
Status : Valid
Issue Date : 2023-05-26
Type : Chemical
Substance Number : 1405
Certificate Number : R1-CEP 2004-306 - Rev 01
Status : Valid
Issue Date : 2013-07-02
Type : Chemical
Substance Number : 1405
Ceftazidime Pentahydrate, Sterile
Certificate Number : R1-CEP 2002-069 - Rev 07
Status : Valid
Issue Date : 2023-06-14
Type : Chemical
Substance Number : 1405
Ceftazidime Pentahydrate With Sodium Carbonate F...
Certificate Number : R1-CEP 2010-096 - Rev 04
Status : Valid
Issue Date : 2023-05-25
Type : Chemical
Substance Number : 2344
Ceftazidime Pentahydrate, Sterile
Certificate Number : R1-CEP 2011-390 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2018-11-21
Type : Chemical
Substance Number : 1405
Ceftazidime Pentahydrate With Sodium Carbonate F...
Certificate Number : R0-CEP 2019-231 - Rev 01
Status : Valid
Issue Date : 2021-11-15
Type : Chemical
Substance Number : 2344
Ceftazidime Pentahydrate, Sterile
Certificate Number : R1-CEP 2016-195 - Rev 00
Status : Valid
Issue Date : 2022-11-10
Type : Chemical
Substance Number : 1405
Ceftazidime Pentahydrate With Sodium Carbonate F...
Certificate Number : R1-CEP 2010-125 - Rev 03
Status : Valid
Issue Date : 2021-01-06
Type : Chemical
Substance Number : 2344
Ceftazidime Pentahydrate With Sodium Carbonate F...
Certificate Number : R1-CEP 2010-272 - Rev 01
Status : Valid
Issue Date : 2019-05-03
Type : Chemical
Substance Number : 2344
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : RX
Registration Country : USA
Brand Name : AVYCAZ
Dosage Form : POWDER;INTRAVENOUS
Dosage Strength : EQ 0.5GM BASE;2GM/VIAL
Packaging :
Approval Date : 2015-02-25
Application Number : 206494
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Italy
Brand Name : CEFTAZIDIME THINK
Dosage Form : Powder And Solvent For Injection
Dosage Strength : 1 g/3 ml
Packaging : 1 UNIT 1000 MG - PARENTERAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name :
Dosage Form : Injection
Dosage Strength : 250MG/1Vial
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : United Kingdom
Brand Name :
Dosage Form : Powder for injection
Dosage Strength : 1G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : United Kingdom
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Fresenius Ceftazidime 2 000 mg
Dosage Form : INJ
Dosage Strength : 2000mg
Packaging : 50X10mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CEPTAZ
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10GM/VIAL
Packaging :
Approval Date : 1990-09-27
Application Number : 50646
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Italy
Brand Name : Glazid
Dosage Form : Ceftazidima 250Mg 1 Unit Parenteral Use
Dosage Strength : 1 vial IM 250 mg + 1 ampoule solv 1 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : RX
Registration Country : USA
Brand Name : TAZICEF
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1GM/VIAL
Packaging :
Approval Date : 1986-03-06
Application Number : 62662
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Powder for Injection
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info :
Registration Country : Norway
Brand Name : Ceftazidim Stragen
Dosage Form : Powder for injection fluid, resolution
Dosage Strength : 1 000 mg
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name :
Dosage Form : Injection
Dosage Strength : 500MG/1Vial
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 500MG/1Vial
Brand Name :
Approval Date :
Application Number :
Registration Country : Italy
Regulatory Info :
Registration Country : Romania
Brand Name : CEFTAMIL®
Dosage Form : powder for injection/I...
Dosage Strength : 1G
Packaging : Box x 1 vial, Box x 10 vials Box x 50 vials
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Romania
Packaging : Box x 1 vial, Box x 10 vials Box x 50 vials
Regulatory Info :
Dosage : powder for injection/I...
Dosage Strength : 1G
Brand Name : CEFTAMIL®
Approval Date :
Application Number :
Registration Country : Romania
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 500MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 1.125G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 1.125G
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic
Registration Country : Pakistan
Brand Name : Biozid
Dosage Form : INJECTION
Dosage Strength : 1G
Packaging : as per requirement
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Pakistan
Packaging : as per requirement
Regulatory Info : Generic
Dosage : INJECTION
Dosage Strength : 1G
Brand Name : Biozid
Approval Date :
Application Number :
Registration Country : Pakistan
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : INJECTABLE
Dosage Strength : 1000MG
Packaging : Vial
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging : Vial
Regulatory Info : Generic
Dosage : INJECTABLE
Dosage Strength : 1000MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Italy
Brand Name :
Dosage Form : Powder for Injection
Dosage Strength : 250MG/ML
Packaging : 1 vial powder + 1 ampoule of 1 ml water for injection
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Packaging : 1 vial powder + 1 ampoule of 1 ml water for injection
Regulatory Info :
Dosage : Powder for Injection
Dosage Strength : 250MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name :
Dosage Form : Powder for Injection
Dosage Strength : 500MG/1.5ML
Packaging : 1 vial powder + 1 ampoule of 1,5 ml water for injection
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Packaging : 1 vial powder + 1 ampoule of 1,5 ml water for injection
Regulatory Info :
Dosage : Powder for Injection
Dosage Strength : 500MG/1.5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Italy
Regulatory Info :
Registration Country :
Brand Name :
Dosage Form : Powder for Solution fo...
Dosage Strength : 2G
Packaging : 1 and 10 vials
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Packaging : 1 and 10 vials
Regulatory Info :
Dosage : Powder for Solution fo...
Dosage Strength : 2G
Brand Name :
Approval Date :
Application Number :
Registration Country :
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Injection
Dosage Strength : 2GM
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 2GM
Brand Name :
Approval Date :
Application Number :
Registration Country : China
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
20 Dec 2024
Reply
04 Oct 2024
Reply
12 Jul 2024
Reply
25 Jan 2023
Reply
07 Oct 2022
Reply
29 Aug 2022
Reply
25 Apr 2022
Reply
14 Feb 2022
Reply
29 Dec 2021
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A AVYCAZ manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AVYCAZ, including repackagers and relabelers. The FDA regulates AVYCAZ manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AVYCAZ API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AVYCAZ manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A AVYCAZ supplier is an individual or a company that provides AVYCAZ active pharmaceutical ingredient (API) or AVYCAZ finished formulations upon request. The AVYCAZ suppliers may include AVYCAZ API manufacturers, exporters, distributors and traders.
click here to find a list of AVYCAZ suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A AVYCAZ DMF (Drug Master File) is a document detailing the whole manufacturing process of AVYCAZ active pharmaceutical ingredient (API) in detail. Different forms of AVYCAZ DMFs exist exist since differing nations have different regulations, such as AVYCAZ USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A AVYCAZ DMF submitted to regulatory agencies in the US is known as a USDMF. AVYCAZ USDMF includes data on AVYCAZ's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AVYCAZ USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of AVYCAZ suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The AVYCAZ Drug Master File in Japan (AVYCAZ JDMF) empowers AVYCAZ API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the AVYCAZ JDMF during the approval evaluation for pharmaceutical products. At the time of AVYCAZ JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of AVYCAZ suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a AVYCAZ Drug Master File in Korea (AVYCAZ KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AVYCAZ. The MFDS reviews the AVYCAZ KDMF as part of the drug registration process and uses the information provided in the AVYCAZ KDMF to evaluate the safety and efficacy of the drug.
After submitting a AVYCAZ KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AVYCAZ API can apply through the Korea Drug Master File (KDMF).
click here to find a list of AVYCAZ suppliers with KDMF on PharmaCompass.
A AVYCAZ CEP of the European Pharmacopoeia monograph is often referred to as a AVYCAZ Certificate of Suitability (COS). The purpose of a AVYCAZ CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of AVYCAZ EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of AVYCAZ to their clients by showing that a AVYCAZ CEP has been issued for it. The manufacturer submits a AVYCAZ CEP (COS) as part of the market authorization procedure, and it takes on the role of a AVYCAZ CEP holder for the record. Additionally, the data presented in the AVYCAZ CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the AVYCAZ DMF.
A AVYCAZ CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. AVYCAZ CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of AVYCAZ suppliers with CEP (COS) on PharmaCompass.
A AVYCAZ written confirmation (AVYCAZ WC) is an official document issued by a regulatory agency to a AVYCAZ manufacturer, verifying that the manufacturing facility of a AVYCAZ active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting AVYCAZ APIs or AVYCAZ finished pharmaceutical products to another nation, regulatory agencies frequently require a AVYCAZ WC (written confirmation) as part of the regulatory process.
click here to find a list of AVYCAZ suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AVYCAZ as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AVYCAZ API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AVYCAZ as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AVYCAZ and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AVYCAZ NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AVYCAZ suppliers with NDC on PharmaCompass.
AVYCAZ Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AVYCAZ GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AVYCAZ GMP manufacturer or AVYCAZ GMP API supplier for your needs.
A AVYCAZ CoA (Certificate of Analysis) is a formal document that attests to AVYCAZ's compliance with AVYCAZ specifications and serves as a tool for batch-level quality control.
AVYCAZ CoA mostly includes findings from lab analyses of a specific batch. For each AVYCAZ CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AVYCAZ may be tested according to a variety of international standards, such as European Pharmacopoeia (AVYCAZ EP), AVYCAZ JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AVYCAZ USP).
LOOKING FOR A SUPPLIER?